Article

Protocol allows fast-track production of RPE cells

A team of scientists reports that it has found a way to isolate retinal pigment epithelium cells from human pluripotent stem cells as early as 14 days following the onset of differentiation.

 

Santa Barbara, CA-A team of scientists at the University of California, Santa Barbara (UCSB) reports that it has found a way to isolate retinal pigment epithelium (RPE) cells as early as 14 days following the onset of differentiation.

Protocols to generate RPE from human pluripotent stem cells are time-consuming and relatively inefficient.

However, in the latest issue of Stem Cells Translational Medicine, the UCSB research team, led by Dennis Clegg, PhD, Peter Coffey, PhD, and David Buchholz, PhD, report that they based their study on earlier reports that neural retinal progenitors could be generated through the application of a handful factors.

“As RPE and the neural retina arise from a common progenitor pool, we sought to determine whether this protocol could be altered to direct pluripotent stem cells to RPE with a similar efficiency,” Dr. Clegg said. “Through the combined use of the retinal inducing factors . . . and other factors added at specific times, we found that pluripotent stem cells could be directed to RPE . . . with an efficiency of about 80%-and it only took 14 days.”

“This study shows that it is now possible to produce homogeneous cultures in a shorter period of time,” said James Thomson, VMD, PhD, a Wisconsin-based researcher who was the first to isolate human embryonic stem cells.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.